1. Introduction {#s0005}
===============

Amongst the biomolecules the proteins are the most important and are involved in numerous biological processes. Protein content in biological fluids is of diagnostic value for determination of several diseased conditions and is also of an immense value in the chemical investigations ([@b0055], [@b0205], [@b0140]). The protein and drug interaction, protein structure and functional changes on biological performance is of great interest to the researchers ([@b0090], [@b0040]).

In the transportation and disposition of drugs in biological system serum albumin present in the blood plasma plays a major role. The extensive study of BSA as model protein for these interaction is because of its structural homology to the human serum albumin ([@b0085], [@b0150]). Structurally BSA consists of three homologous domains and each of these domains consist of two sub-domains namely sub-domain IA, IB, IIA, IIB, IIIA, and IIIB. These sub-domains of BSA are involved in binding the endogenous and/or exogenous ligands. The ligand binding sites of BSA are located in the hydrophobic cavities of sub-domains IIA and IIIA ([@b0040]).

The biological activities of N-substituted phthalimides is well established ([@b0025], [@b0065], [@b0125], [@b0120]). The anti-hyperlipidemic and anti-diabetic potential of these compounds have been explored ([@b0060], [@b0210]) The mechanism of hypolipidemic activity of N-substituted phthalimides is supposed to be due to their inhibitory activity against acetyl-CoA ([@b0060], [@b0010]). The studied compound **5e** ([Fig. 1](#f0005){ref-type="fig"}) ([@b0005]) was found to lower the serum glucose in diabetic rate by 55% and the reduction was more than the standard drug glibenclamide which showed only 51% reduction in the serum glucose levels of diabetic rats. Further, **5e** decreased the cholesterol and triglyceride levels more efficiently than the positive control glibenclamide ([@b0005]).Fig. 1Chemical structure of 5,6-Dichloro-2-\[2-(pyridin-2-yl)ethyl\]isoindoline-1,3-dione (**5e**).

Pharmacokinetic and pharmacodynamics of a drug is dependent on the drug-protein interaction. Fluorescence technique are particularly used to explore ligand protein interactions ([@b0015], [@b0155], [@b0165], [@b0175], [@b0160]). The affinity of **5e** for BSA was investigated in this study and thus, explore the carrier role of BSA for **5e** under physiological conditions. The binding studies are helpful in understanding the interaction mechanism and designing of suitable ligands. In addition to the fluorescence quenching study, conformational changes in the BSA post interaction were also studied by UV--visible spectroscopy, synchronous fluorescence (SF), and three-dimensional spectroscopy. Different temperatures were used to carry out the binding studies and evaluate the involved thermodynamic processes. Molecular docking studies were also carried out for the ligand and the BSA protein and the obtained results were related to the spectroscopic experimental results.

2. Materials and methods {#s0010}
========================

2.1. Materials {#s0015}
--------------

The materials and their procuring sources were as follows: Fatty acid free BSA (Sigma Aldrich; USA); Ibuprofen and phenylbutazone (National Scientific Company; KSA). The **5e** was synthesized ([@b0005]) in synthetic chemistry laboratory of Pharmaceutical Chemistry Department; College of Pharmacy; King Saud University. The BSA, **5e**, ibuprofen and phenylbutazone stocks were prepared in phosphate buffer (pH 7.4). The water used for buffer preparation was from Elga Purelab (Elga Lab Water UK). Materials of analytical purity were used for the analysis.

2.2. Instrumentation {#s0020}
--------------------

The fluorescence emission spectra were recorded at three temperatures 298, 305 and 310 K using JASCO spectrofluorometer. A slit width of 5 nm was used for attaining both excitation and emission spectra. An excitation wavelength of 280 nm and emission wavelength of 300--500 nm was used to obtain the fluorescence spectra. The UV--vis absorption spectra were recoded using UV-1800 spectrophotometer from Shimadzu (Japan) The spectra were recorded in the range of 200--500 nm.

2.3. Fluorescence spectral and UV--Vis spectral measurement {#s0025}
-----------------------------------------------------------

The fluorescence spectra of BSA and BSA-**5e** complex were recorded. A fixed concentration of BSA and variable concentrations of **5e** were used to record the spectra. Inner filter effect can lead to reduced fluorescence intensity (FI) and therefore need to be corrected. The inner filter effects were corrected with the equation:$$F_{\mathit{cor}} = F_{\mathit{obs}} \times e^{(A_{\mathit{ex}} + A_{\mathit{em}})/2}$$

The fluorescence (corrected and observed) were represented by F*~cor~* and F*~obs~* respectively. The absorption at the excitation and emission wavelength of **5e** were denoted by A~ex~ and A*~em~.*

The UV--Vis spectra were recorded at room temperature (298 K) for the BSA and BSA-**5e** complex (fixed BSA concentration and increasing **5e** concentration).

2.4. Synchronous fluorescence (SF)spectral measurement and site binding studies {#s0030}
-------------------------------------------------------------------------------

SF spectra for **5e** and BSA-**5e** complexes were recorded at room temperature (298 K). The scanning intervals Δλ ((Δλ = λ ~em~ − λ~ex~) equal to 15 and 60 nm were used to record the spectra. The intervals of Δλ = 15 nm and 60 nm characterize the tyrosine (Tyr) and tryptophan (Trp) residues respectively. Binding site identification for **5e** on BSA was carried out using displacement studies for site specific markers phenylbutazone and ibuprofen.

2.5. Molecular docking {#s0035}
----------------------

Molecular simulation experiments were done to study the BSA-**5e**-binding interaction. The interaction was studied using Molecular Operating Environment (MOE) software. Naproxen co-crystallized structure of BSA was acquired from protein data bank; pdb code:[4OR0](pdb:4OR0){#ir005} and the **5e** structure was drawn within MOE ([@b0200], [@b0050]). BSA consists of two homodimer chains, named as A and B. These studies were conducted using the chain B of the BSA homodimer.

3. Results and discussions {#s0040}
==========================

3.1. Fluorescence studies {#s0045}
-------------------------

The amino acid residues Trp and Tyr are primarily responsible for a protein's intrinsic fluorescence. It has also been observed that a protein ligand interaction usually reduces the fluorescence intensity of the protein and this reduction is ligand concentration dependent. Thus, the protein ligand interaction can be explored with the help of fluorescence quenching studies. (Chu et al., 2010).

The fluorescence spectra were recorded for BSA whose concentration was held constant and the **5e** concentration was varied. ([Fig. 2](#f0010){ref-type="fig"}). A reduction in FI of BSA occurred post interaction with **5e** and got further reduced with increasing **5e** concentration suggesting fluorescence quenching. The fluorescence spectra of BSA-**5e** showed a blue shift indicating that the chromophore in the serum albumin shifted towards a more hydrophobic microenvironment. The involved quenching mechanisms could be either static or dynamic quenching or combined dynamic and static quenching ([@b0035], [@b0145], [@b0190]). These two mechanisms are distinguished from one another based on their dependency on temperature and viscosity ([@b0080]). At high temperatures large diffusion coefficients are observed in dynamic quenching and are further increased with rise in temperature. However, in static quenching as the temperature increases the stability of protein--ligand complex decreases leading to lower quenching constants. However, in case of combined dynamic and static quenching both collision and complex formation occur with the same quencher.Fig. 2Fluorescence spectra of BSA (1.5 μM) in the presence of **5e** at 298 K; (**5e** concentration (1.49 × 10^−6^, 2.99 × 10^−6^, 5.98 × 10^−6^,1.49 × 10^−5^, 5.97 × 10^−6^, 1.79 × 10^−5^).

3.2. Quenching mechanism analysis {#s0050}
---------------------------------

Stern-Volmer equation was used to elucidate the quenching mechanism between BSA and **5e** ([@b0070]).$$\frac{F_{0}}{F} = 1 + K_{\mathit{sv}}\left\lbrack Q \right\rbrack = 1 + k_{q}\tau_{0}{\lbrack Q\rbrack}$$F and F~0~ are the FI of BSA in presence and absence of **5e** respectively. K~sv~ represents the Stern -Volmer constant; \[Q\] Quencher concentration; k~q~ quenching rate constant; τ~0~ excited state lifetime of fluorophore and is valued 10^−8^ S for biomolecules ([@b0070], [@b0195], [@b0170], [@b0045]).

[Fig. 3](#f0015){ref-type="fig"}A represents the plot between F~0~/F and **5e** at the different temperatures. The plots exhibited a good linear relationship and the results are given in [Table 1](#t0005){ref-type="table"}. The K~sv~ values decreased at higher temperatures indicating formation of a ground state complex between BSA and **5e**. Formation of complex between BSA and **5e** infers involvement of static quenching. The maximum achievable value for the dynamic quenching constant for biopolymers is 2 × 10^10^ LM^−1^ S^−1^ ([@b0180]). The quenching constant values attained were greater than 2 × 10^10^ LM^−1^ S^−1^ as given in [Table 1](#t0005){ref-type="table"}, further indicates the formation of complex and involvement of static quenching between BSA and **5e**.Fig. 3The plots for interaction between BSA with **5e** at different temperatures **\[**A\]: Stern--Volmer Plot, \[B\]: Binding Constant log \[(F~0~- F)/F\] Vs log\[Q\], \[C\]: Van't Hoff Plot, \[D\]: Binding constant in presence of site markers at 298 K.Table 1K~SV~ and K~q~ values for the binding interaction of **5e** and BSA at different temperatures.T(K)RK~sv~ ± SD × 10^4^ (L mol^−1^)k~q~ × 10^12^ (L mol^−1^ s^−1^)2980.99581.36 ± 0.0251.363050.99931.26 ± 0.0161.263100.99731.20 ± 0.0201.20

3.3. Binding constant and binding site {#s0055}
--------------------------------------

Therapeutic potential of drugs depends on the in-vivo binding potential of these drugs and this ability can influence their stability and toxicity in a therapeutic process. The binding interaction evaluation between BSA and **5e** was based on the binding constants calculated from FI data obtained at different temperatures. The free and bound molecular equilibrium is given by the double log regression curve ([@b0185], [@b0095], [@b0105]. The following equation represents this equilibrium:$$log\frac{(F_{0} - F)}{F} = logK_{b} + nlog{\lbrack Q\rbrack}$$

In the plot log \[(F~0~ − F)/F\] Vs log \[Q\] ([Fig. 3](#f0015){ref-type="fig"}B), slope 'n' represents stoichiometry of binding and the binding constant K~b~ is calculated from the intercept ([Table 2](#t0010){ref-type="table"}). Single binding site for **5e** present on BSA molecule is inferred from the fact that n is approximately equal to unity. This binding strength determines the ability of the drug to diffuse from the bound protein to its target of action ([@b0100], [@b0020]). The ligands bind to the protein mostly in a reversible fashion and exhibit the binding affinities ranging from (1--15) × 10^4^ L M^−1^ ([@b0030]). The K~b~ values obtained showed a decrease at higher temperatures indicating instability of BSA-**5e** complex. Also, the complex formed may be reversible since the binding between BSA and **5e** is moderate.Table 2Binding and thermodynamic parameter values for the binding interaction of **5e** and BSA at different temperatures.T(K)RLog K~b~ ± SDK~b~ (L mol^−1^)nΔG (kJ mol^−1^)ΔH (kJ mol^−1^)ΔS (J mol^−1^ K^−1^)2980.98874.23 ± 0.0131.70 × 10^4^0.98−26.48−172−4853050.98743.94 ± 0.0168.71 × 10^3^0.92−24.543100.98953.66 ± 0.0104.57 × 10^3^0.87−22.11

3.4. Binding site identification {#s0060}
--------------------------------

The binding site identification of **5e** on BSA was carried out by site competition of **5e** with site specific markers phenylbutazone and ibuprofen ([@b0110]). Phenylbutazone is specific marker for site I whereas, ibuprofen is specific marker for site II of BSA. A reduction in FI of BSA was observed on addition of phenylbutazone and ibuprofen. However, phenylbutazone caused a higher decrease in the fluorescence intensity compared to ibuprofen. The calculated binding constants for BSA-**5e**, BSA-phenylbutazone-**5e**, and BSA-ibuprofen-**5e** were 1.62 × 10^4^, 0.48 × 10^2^ and 0.91 × 10^3^ respectively ([Fig. 3](#f0015){ref-type="fig"}D). Lower binding constants were observed for the phenylbutazone and ibuprofen complexes in comparison to the BSA-**5e**. Site I (phenylbutazone) Sub-domain IIA as the binding site for **5e** was concluded from the fact that the decrease in the binding constant was much more than that observed for ibuprofen.

3.5. Synchronous fluorescence (SF) and Three-dimensional (3D) studies {#s0065}
---------------------------------------------------------------------

The SF spectroscopy is mostly utilized to characterize and understand the effect of interaction between the protein and ligand. The SF spectroscopy gives information about microenvironment of chromophores present in the protein. The two amino acid residues mainly involved in the fluorescence of proteins are Trp, Tyr, and Phe. The difference Δλ (Δλ = λ ~em~ − λ~ex~) ([@b0070]) reflects the spectral characteristics and nature of chromophores. The effect of varied concentrations of **5e** addition on the fluorescence quenching of Tyr and Trp residues of BSA at Δλ = 15 and 60 nm respectively was studied. No change was observed in the emission wavelengths at either Δλ = 15 or 60 nm ([Fig. 4](#f0020){ref-type="fig"}). Therefore, it is suggested that the amino acid residues Trp and Tyr polarity present in BSA was slightly altered by **5e**.Fig. 4Synchronous fluorescence of BSA-**5e** complex at 298 K \[A\] Δλ = 15 nm and \[B\] Δλ = 60 nm.

The 3D fluorescence spectroscopy provides information regarding the configurational changes that might have occurred in the protein after interacting with the ligands ([@b0075]). The 3D data is presented in the ([Fig. 5](#f0025){ref-type="fig"}) and the two peaks found were Peak I and Peak II. The Peak I and II were observed at the excitation wavelength of 230 and 280 nm respectively. Peak I is attributed to the pi-pi transition of polypeptides (Rayleigh scattering peak) whereas, Peak II is attributed to the fluorescent amino acid residues present in BSA. Peak II is attributed to the intrinsic fluorescence of tryptophan and tyrosine residues. These amino acid residues are linked to the conformational changes in the peptide backbone that is associated with helix-transformation. Since there was considerable reduction in BSA fluorescence intensity post **5e** addition, it was concluded that peptide backbone (tryptophan and tyrosine) was altered. Thus, conformational changes are suggested to have occurred in BSA indicating complex formation between the BSA and **5e**.Fig. 5Three-dimensional fluorescence analysis, BSA \[A\]: BSA-**5e** Complex \[B\].

3.6. Thermodynamic studies {#s0070}
--------------------------

The interaction forces that might occur between the proteins and ligands are established with the help of thermodynamic studies. The type of the interaction between protein and the ligand are characterized by their signs and the magnitude of thermodynamic parameters. The following thermodynamic parameters (ΔG°^)^ Gibbs free energy; (ΔH°) change of enthalpy and (ΔS°) change of entropy were explored to identify the interaction forces between **5e** and BSA ([@b0115]). Value of ΔH° \> 0 and ΔS° \> 0, indicate hydrophobic interaction forces whereas, ΔH°^0^ \< 0 and ΔS°^0^ \< 0 indicate van der Waals forces and hydrogen-bonding. Electrostatic forces are said to be involved in the interaction in case ΔH° \< 0 and ΔS° \> 0.

Van\'t Hoff equation was used to calculate the thermodynamic interaction parameters:$${lnK}_{b} = - \frac{\Delta H{^\circ}}{\mathit{RT}} + \frac{\Delta S{^\circ}}{R}$$where K~b~ is the binding constant, R is the universal gas constant, T is temperature in kelvins. The slope of the van\'t Hoff equation gives us the enthalpy change ΔH°~.~ The free energy change is given with the equation:$$\Delta G{^\circ} = \Delta H{^\circ} - T\Delta S{^\circ} = - RTlnK_{b}$$

The thermodynamic parameters were calculated from the van\'t Hoff plot ([Fig. 3](#f0015){ref-type="fig"}C). The thermodynamic results in [Table 2](#t0010){ref-type="table"} indicate that the interaction between BSA and **5e** was spontaneous in nature since, ΔG° attained a negative value. Since both ΔH° and ΔS° were negative and therefore, suggested an enthalpy driven interaction between BSA and **5e**.

3.7. UV--vis absorption studies {#s0075}
-------------------------------

The UV--vis absorption methodology was used to study the possible BSA structural alterations and BSA and **5e** complex ([@b0130], [@b0135]). Spectra for UV-absorption of BSA (1.5 μM) alone and in presence of **5e** at room temperature were recorded ([Fig. 6](#f0030){ref-type="fig"}). The following **5e** concentrations used were (1.49 × 10^−6^, 2.99 × 10^−6^, 5.98 × 10^−6^, 1.49 × 10^−5^ and 1.79 × 10^−5^) for the analysis. The UV-absorption spectra display in the range influence of **5e** on the absorption spectrum of BSA. The spectrum showed two bands of absorption for BSA and the stronger band occurred at 210 and whereas the weak band occurred at near 280 nm. The 210 nm band characterize conformational structure of the BSA whereas, the 280 nm band characterizes the π → π transition because of aromatic amino acids. An increased absorption intensity was detected at both the band points as the concentration of **5e** was increased suggesting formation of complex between BSA and **5e**. Further, a redshift was seen at near 210 nm in the absorption spectrum which also indicated complex formation.Fig. 6UV-absorption spectra of BSA and BSA-**5e** complex.

3.8. Molecular modeling study {#s0080}
-----------------------------

The docking was carried out to further ascertain the BSA binding site to bind **5e** ([Fig. 7](#f0035){ref-type="fig"}). The binding energy of **5e** at sub-domain IIA was −26.63 kJ mol^−1^, and was lower than the binding energy of **5e** on sub-domain IIIA (−25.31 kJ mol^−1^). This indicated the preferred binding site for **5e** to be site I of subdomain IIA and the similar results were seen in binding site identification studies. Also, **5e** was observed to be inside the hydrophobic cavity of site I; [Fig. 7](#f0035){ref-type="fig"}A.Fig. 7\[A\] Three dimensional representation of the interaction of **5e** with BSA. \[B\] A two dimensional representation of amino acids that surround **5e**.

These results clearly help in understanding the fluorescence quenching behavior of BSA emission in presence of **5e** ([@b0130], [@b0135]). The docking results are also in agreement with the thermodynamic studies as hydrogen bonds were seen between the Arg-198 and **5e** whereas, Pi-H bonds were observed between Arg-194 and Trp-213 residues of BSA ([Fig. 7](#f0035){ref-type="fig"}B). The docking results also showed that **5e** interacted with hydrophobic amino acids (Ala-209, Val-481, Val-342, Leu-480, Leu-346, Leu-197. Polar amino acid residues (Trp-213, Ser-201, Ser-343) and charged residues (Arg-217, Arg-198, Arg-194, Asp-450) also interacted with **5e**. The free binding energy (−26.63 kJ mol^−1^) from the docking procedures was close to the free binding energy value obtained experimentally ([Table 2](#t0010){ref-type="table"}).

4. Conclusion {#s0085}
=============

Different spectroscopic methods were used for the detailed study of interaction hypoglycemic compound **5e** with BSA. Experimental and docking approaches were used to explore this interaction. BSA and **5e** formed a complex and static fluorescence quenching mechanism is suggested to be involved in the interaction. The negative Gibbs free energy suggested a spontaneous interaction between BSA and **5e**. The thermodynamic results also suggested involvement of hydrogen-bonding in the interaction. Conformational changes were also suggested in the BSA after interaction with **5e**. All these results indicate that **5e** can bind to serum albumin, thus, this study can be of helpful in further pharmacokinetic development of **5e**.
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